MBBS BSc (Hons) MRCP
Medical Research Council Clinical Research Training Fellow
Dr Rahul Ravindran graduated in Medicine from Imperial College London, where he won numerous prizes and distinctions including the prestigious University of London Gold Medal out of over 1600 medical students. During this time he intercalated in Immunity & Infection, conducting research with Professor Dorian Haskard at the National Heart and Lung Institute, for which he received First Class Honours, and which sparked his desire to pursue an academic clinical career.
Dr Ravindran undertook Integrated Academic Training (IAT) in Oxford, securing a highly competitive National Institute for Health and Care Research (NIHR) Academic Foundation position, followed by an NIHR Academic Clinical Fellowship in Gastroenterology. He utilised this time to build his research interest in tissue inflammation in the intestine and was successful in winning a Medical Research Council Clinical Research Training Fellowship to undertake research in how the lymphatic vasculature plays a role in the resolution of intestinal inflammation at the Kennedy Institute of Rheumatology under the leadership of Professor Chris Buckley, Professor Fiona Powrie and Dr Matthias Friedrich. He has developed experience in running and analysing in vivo models of intestinal inflammation as well as conducting in silico analysis of transcriptomic data at the single cell level. For his research he received a Keeley Scholarship from Wadham College, Oxford.
Dr Ravindran is passionate about teaching and is an Associate Fellow of the Higher Education Academy. He is registered with the General Medical Council and is a Member of the Royal College of Physicians. He is also a member of the British Society for Immunology, the British Society of Gastroenterology and the Society for Mucosal Immunology.
Driven by a deep interest in bridging academia and industry for the advancement of patient care, Dr Ravindran is embarking on a secondment at AstraZeneca via the Medical Research Council in 2024 where he will be engaging in early-phase clinical trials in inflammation. His overarching desire is to expedite innovative therapeutics to patients suffering with inflammatory diseases across all tissues.